Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Stemline Therapeutics: Additional patient death raises safety concerns with SL-401, but unlikely to put approvability in BPDCN at risk — Wedbush (10.15)Wedbush expects the reported patient fatality in the Ph 2 SL-401 study in high-risk MPN to put near-term pressure on stock, but continue to view risk/reward as favorable going into BPDCN data and potential filing later this year. However, this death, coming soon after a fatality reported in the BPDCN study, highlights potential risk to approval. Additionally, although data are too limited to draw firm conclusions, <strong>firm would lean to the death not being drug-related.</strong> Pericardial effusion (buildup of excess fluid in heart sac) has not been linked to SL-401 previously, but is a manifestation of certain MPNs that can lead to potentially fatal cardiac complications. At this time firm does not believe the AE has any readthrough over to BPDCN, which they note is the only indication they model SL-401 sales in; Outperform, $11 tgt.</td> </tr></table>"